CRDF News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CR

Volume

455.45K

Next Earnings

November 5th

Loading chart

CR

CRDFCardiff Oncology, Inc. Common Stock

CRDF

Pay with—

Available Balance0.00

CR

Mkt Cap

$75.7M

Volume

455.45K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Cardiff Oncology to Participate in September 2026 ConferencesCardiff Oncology announced that Dr. Mani Mohindru will present at two upcoming conferences in September 2026, discussing the company's PLK1 inhibitor onvansertib for RAS-mutated metastatic colorectal cancer treatment. The company is advancing its lead asset through Phase 2 trials with positive data previously presented at ASCO.GlobeNewswire Inc. · Sep 2, 2026

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRCCardiff Oncology announced updated Phase 2 CRDF-004 data for onvansertib, a PLK1 inhibitor, will be presented at ASCO 2026 on June 2, 2026, with an investor webcast scheduled for June 3, 2026. The company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational Phase 3 trial for first-line RAS-mutated metastatic colorectal cancer, following positive dose-dependent improvements in response rates and progression-free survival.GlobeNewswire Inc. · May 21, 2026

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026Cardiff Oncology announced it will present updated interim data from its Phase 2 CRDF-004 trial evaluating onvansertib, a PLK1 inhibitor, combined with standard chemotherapy and bevacizumab for first-line treatment of RAS-mutated metastatic colorectal cancer at the ASCO 2026 Annual Meeting in Chicago on June 2, 2026.GlobeNewswire Inc. · Apr 21, 2026

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual MeetingCardiff Oncology announced preclinical data showing its PLK1 inhibitor onvansertib enhanced antitumor activity of trastuzumab deruxtecan and reversed resistance in therapy-resistant HER2-low breast cancer models. The findings will be presented at the AACR Annual Meeting in April 2026. Onvansertib is currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer and other cancers.GlobeNewswire Inc. · Mar 19, 2026

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare ConferenceCardiff Oncology will participate in the Piper Sandler 37th Annual Healthcare Conference, with CEO Mark Erlander presenting on December 2, 2025, discussing their PLK1 inhibition cancer therapies and lead asset onvansertib.GlobeNewswire Inc. · Nov 24, 2025

KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsightThe KRAS inhibitors market is projected to grow at a 35% CAGR from 2025-2034, driven by rising cancer incidence and a robust pipeline of targeted therapies for KRAS mutations across multiple cancer types.GlobeNewswire Inc. · Nov 12, 2025

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the ChargeThe global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.Benzinga · Mar 8, 2025

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingCardiff Oncology, a clinical-stage biotechnology company, announced the pricing of a $40 million underwritten offering of its common stock. The company plans to use the proceeds to fund clinical trials for its lead asset, onvansertib, in metastatic colorectal cancer and pancreatic cancer.Benzinga · Dec 10, 2024

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical TrialCardiff Oncology announced positive initial data from a randomized Phase 2 trial evaluating onvansertib in combination with standard-of-care in patients with first-line RAS-mutated metastatic colorectal cancer. The 30mg dose of onvansertib demonstrated a 64% objective response rate, significantly higher than the 33% rate in the control arm.GlobeNewswire Inc. · Dec 10, 2024

Cardiff Oncology to Present at the Jefferies Healthcare ConferenceSAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.GlobeNewswire Inc. · May 29, 2024

to start trading

CR

CRDFCardiff Oncology, Inc. Common Stock

CRDF

Pay with—

Available Balance0.00

Your PositionYou don't own any CRDF yet.

Related Tickers

Earnings